尼妥珠单抗联合吉西他滨一线治疗KRAS野生型晚期胰腺癌的随机IIb期研究
这项多中心随机IIb期研究比较吉西他滨联合尼妥珠单抗与吉西他滨联合安慰剂一线治疗局部晚期或转移性胰腺癌的疗效。192例患者随机分组,186例可评估。联合组1年OS/PFS为34%/22%,安慰剂组为19%/10%(HR=0.69,P=0.03/HR=0.68,P=0.02)。中位OS/PFS联合组为8.6/5.1个月,对照组为6.0/3.4个月。KRAS野生型患者OS显著优于KRAS突变型(11.6 vs 5.6个月,P=0.03)。
要点
- 尼妥珠单抗联合吉西他滨一线治疗晚期胰腺癌安全且耐受良好。
- 联合组1年OS和PFS率显著改善(34%/22% vs 19%/10%)。
- KRAS野生型患者OS显著优于KRAS突变型(11.6 vs 5.6个月,P=0.03)。
核心结论
- 尼妥珠单抗联合吉西他滨安全且耐受良好,全人群1年OS和PFS率显著改善,KRAS野生型患者似乎获益。
研究设计与样本
- 多中心、随机、IIb期研究,192例既往未治疗的不可切除局部晚期或转移性胰腺癌患者随机分组,186例可评估疗效和安全性,平均年龄63.6岁。
主要发现
- 联合组1年OS/PFS为34%/22%,对照组为19%/10%(HR=0.69,P=0.03/HR=0.68,P=0.02)。
- 联合组中位OS/PFS为8.6/5.1个月,对照组为6.0/3.4个月(HR=0.69,P=0.0341/HR=0.68,P=0.0163)。
- KRAS野生型患者OS显著优于KRAS突变型(11.6 vs 5.6个月,P=0.03)。
- 3/4级毒性很少。
关键数值与推荐
- 吉西他滨1000 mg/m2,30分钟静脉输注,每周一次(d1、8、15;q29)。
- 尼妥珠单抗固定剂量400 mg,每周一次,30分钟输注。
- 治疗持续至疾病进展或不可接受的毒性。
临床怎么用
- 尼妥珠单抗联合吉西他滨可作为KRAS野生型局部晚期或转移性胰腺癌的一线治疗选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth factor receptor monoclonal antibody, compared with gem plus placebo as first-line therapy in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Patients with previously untreated, unresectable, locally advanced or metastatic pancreatic cancer were randomly assigned to receive gem: 1000 mg/m2, 30-min i.v. once weekly (d1, 8, 15; q29) and nimo: fixed dose of 400 mg once weekly as a 30-min infusion, or gem plus placebo, until progression or unacceptable toxicity. The primary end point was overall survival (OS), secondary end points included time to progression, overall response rate, safety and quality of life. RESULTS: A total of 192 patients were randomized, with 186 of them being assessable for efficacy and safety (average age 63.6 years). One-year OS/progression-free survival (PFS) was 34%/22% for gem plus nimo compared with 19%/10% for gem plus placebo (HR = 0.69; P = 0.03/HR = 0.68; P = 0.02). Median OS/PFS was 8.6/5.1 months for gem plus nimo versus 6.0/3.4 mo in the gem plus placebo group (HR = 0.69; P = 0.0341/HR = 0.68; P = 0.0163), with very few grade 3/4 toxicities. KRAS wildtype patients experienced a significantly better OS than those with KRAS mutations (11.6 versus 5.6 months, P = 0.03). CONCLUSION: This randomized study showed that nimo in combination with gem is safe and well tolerated. The 1-year OS and PFS rates for the entire population were significantly improved. Especially, those patients with KRAS wildtype seem to benefit. The study was registered as protocol ID OSAG101-PCS07, NCT00561990 and EudraCT 2007-000338-38.
引用
- Schultheis B, Reuter D, Ebert MP, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Ann Oncol. 2017. PMID: 28961832. doi:10.1093/annonc/mdx343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。